Opevesostat
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Opevesostat
- Molecular weight
- 418.52
- Structure (SMILES)
- CS(=O)(=O)N1CCC(COc2coc(CN3Cc4ccccc4C3)cc2=O)CC1
- mk 5684
- MK-5684
- odm 208
- Odm-208
- ODM-208
- odm208
- ODM208
- opevesostat
- Opevesostat
- opevesostat [INN]
- OPEVESOSTAT [USAN]
- Opevesostat [WHO-DD]
- opevesostat inn
- opevesostat usan
- opevesostat who dd
- CAS registry numbers
- 2231294-96-3
- ChEMBL ID
- CHEMBL5314533
- InChIKey
- LHVKCOBGLZGRQZ-UHFFFAOYSA-N
- PubChem compound IDs
- 135151902
- FDA ingredient codes (UNII)
- 1Z7MAV4KQC
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- opevesostat
- Type
- Synthetic organic
- Drug name stem
- -stat
Mechanisms of action
- Action
- Inhibition
- Action type
- Inhibitor
- Target
- CYP11A1
- Gene symbol
- CYP11A1
- Protein identifier
- P05108
- Median affinity
- 6.97
- Affinity units
- pIC50
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition identifier
- EFO_0000673
- Condition identifier
- MONDO_0007254
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008170
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008315
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0011962
- Highest recorded phase
- 2
- NCT03436485
- NCT06104449
- NCT06136598
- NCT06136650
- NCT06353386
- NCT06136624
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 0
- Polar surface area
- 80.06
- Calculated partition coefficient (ALogP)
- 2.21
- Calculated partition coefficient (XLogP)
- 1.3
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 6
- Heavy atoms
- 29
- Molecular formula
- C21H26N2O5S
- Monoisotopic mass
- 418.15624311
- Natural product
- No
Related records
Trials (14)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)
- A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)
- A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)
- A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
- A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
- A Study of Opevesostat (MK-5684) in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
- A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- A Study of the Absorption, Distribution, Metabolism, and Elimination of Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-008)
- A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
- A Study to Evaluate the Effect of MK-5684 in Male Participants With Severe Renal Impairment (RI) and With End-stage Renal Disease (ESRD) (MK-5684-010)
- Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer
- Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
In development for (3)
- Metastatic prostate carcinoma Phase 3
- Prostate adenocarcinoma Phase 3
- Prostate cancer Phase 1